Date: 2017-02-01
Type of information: Grant
Company: Confo Therapeutics (Belgium)
Investors: Flanders Innovation & Entrepreneurship (VLAIO) (Belgium) Innoviris (Belgium)
Amount: €2.57 million
Funding type: grant
Planned used:
- The first grant will mostly be allocated to Confo Therapeutics' Drug Discovery Center in Gent, to discover new GPCR agonist compounds for the treatment of fibrosis.
The grant from Innoviris will be used to further broaden the
applicability of its proprietary Confo® technology.
Others:
- • On February 1, 2017, Confo Therapeutics announced that it
has received a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant has a duration of 2 years. In January, the company was also awarded a €0.97 million grant from Innoviris, the Brussels Institute for the encouragement of scientific research and innovation, to further broaden the applicability of its proprietary Confo® technology.
Therapeutic area: Fibrotic diseases
Is general: Yes
